Myelodysplastic syndromes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

  Syntrix Biosystems, Inc.· Auburn, United States· US$406,500 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · DP2

  Single-molecule, Single-cell profiling of chromatin protein-protein interactions.

  Van Andel Research Institute· Grand Rapids, United States· US$912,000 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  Role of IL-1 beta signaling in stress erythropoiesis

  Pennsylvania State University, the· University Park, United States· US$641,869 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · R01

  Mechanisms underlying germline predisposition to clonal hematopoiesis

  Albert Einstein College of Medicine· Bronx, United States· US$693,151 awarded in fiscal year 2026· until May 2031

• NIH NHGRI · R01

  A single-cell multiomics platform for studying genome structure and function

  University of Washington· Seattle, United States· US$796,114 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility (DiagMDS)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €1,322,640· until Sept 2030· 9 countries

• European Commission (Horizon 2020) · ERC-COG

  Identifying spatial determinants of immune cell fate commitment (ImmuNiche)

  Julius-Maximilians-Universitat Wurzburg· Wuerzburg, Germany· EU contribution €1,997,500· until Dec 2026

7 of 172 running projects, newest first. Listed amounts together: US$105.3m + €3.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Updated 20 Oct 2026

  “The trial closed early due to changes in support for the study drug.”Registry text, quoted unchanged. Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Updated 16 Oct 2025

  “Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.”Registry text, quoted unchanged. Source

• Terminated

  HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

  NCT03940352· Novartis Pharmaceuticals· Updated 10 Oct 2025

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Updated 11 Apr 2024

  “waiting for update from Study Lead”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Source

• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Source

• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Source

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Source

• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• Metabolic mimic of inherited bone marrow failure: LMBRD1 (cblF) deficiency in an infant.

  Int J Hematol, Aug 2026

• Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita.

  Isr Med Assoc J, Aug 2026

• Behçet's syndrome-like features revealing myelodysplastic syndrome with TP53 mutation: a case report.

  Front Immunol, Apr 2026

• Molecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience.

  Res Pract Thromb Haemost, Mar 2026

• A novel frameshift deletion in SLC25A38 and its role in mitochondrial dysfunction: A case study of sideroblastic anemia in a child from Iran.

  Ann Hematol, Feb 2026

• Respiratory complex I deficiency caused by a novel multi-exonic PUS1 deletion.

  J Hum Genet, Dec 2025

• Case Report: VEXAS syndrome with extensive pulmonary, cardiac, and skeletal involvement.

  Front Immunol, Nov 2025

• Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure.

  J Clin Immunol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.